Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation

Danish Medical Journal

Volumn 63, Issue 2, 2016, Pages

  Hansen, Peter Steen ^a   Sanchez, Ricardo ^a   Walfridsson, Håkan ^a,b  

^a Varde Heart Centre   (Denmark)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; RIVAROXABAN; VERAPAMIL; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING TIME; CATHETER ABLATION; CORONARY SINUS; DRUG SAFETY; FEMALE; FOLLOW UP; HEART TAMPONADE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS DRAINAGE; PERICARDIAL EFFUSION; PROSPECTIVE STUDY; PULMONARY VEIN ISOLATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TELECONSULTATION; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; ORAL DRUG ADMINISTRATION; POSTOPERATIVE HEMORRHAGE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; RIVAROXABAN; THROMBOEMBOLISM;

EID: 84956789417     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33:2719-47.
2. Maan A, Heist EK, Ruskin JN et al. Practical issues in the management of novel oral anticoagulants cardioversion and ablation. J Thorac Dis 2015;7:115-31.
3. Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
4. Eitel C, Koch J, Sommer P et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013;15:1587-93.
5. Armbruster HL, Lindsley JP, Moranville MP et al. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Ann Pharmacother 2015;49:278-84.
6. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15:1407-11.
7. Stepanyan G, Badhwar N, Lee RJ et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electro­physiol 2014;40:33-8.
8. Arshad A, Johnson CK, Mittal S et al. Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study. Pace 2014;37:665-73.
9. Providência R, Marijon E, Albenque J-P et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014;16:1137-44.
10. Cappato R, Marchlinski FE, Hohnloser SH et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in nonvalvular atrial fibrillation. Eur Heart J 2015;36:1805-11.
11. Di Biase L, Natale A. Apixaban is dear to me, but dearer still is Warfarin. PACE 2015;38:153-4.
12. Biase LD. Safety and efficacy of novel oral anticoagulants in the setting of atrial fibrillation ablation: Is it time to celebrate the “funeral” of warfarin. J Interv Card Electrophysiol 2014;41:103-512.